http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-11201407644U-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0278
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
filingDate 2013-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a22d49d1d61d486248bdb69b148c650
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b281684868fab832a8c93c5107464d96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bf19d0875178cd70466b49035c7a85c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df25ebad11b4626dbe8036244088360b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_973ff7ce33b9c5f730a90445e1a94cfb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_020b6fc7e3d3e8c1725d95370cf1673b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b0e65f6722dab22c8233aa56f25f2bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fde233b508ce25f82fe549de4f9f298c
publicationDate 2014-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber SG-11201407644U-A
titleOfInvention Methods for making fully human bispecific antibodies using a common light chain
abstract (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/184761 A1 (51) International Patent Classification: A01K 67/027 ( 2006.01) C07K16/40 (2006.01) C07K16/00 (2006.01) C12N15/85 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 13/488,628 5 June 2012 (05.06.2012) (74) Agent: KOWALCHYK, Katherine, M.; Merchant & Gould P.C., P.O. Box 2903, Minneapolis, MN 55402-0903 (US). PCT/US2013/044257 5 June 2013 (05.06.2013) English (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591-(US). (72) Inventors: BABB, Robert; 292 Voorhis Avenue, River Edge, NJ 07661 (US). MCWHIRTER, John; 2035 Cres­ cent Drive, Tarrytown, NY 10591 (US). MACDONALD, Lynn; 16 Gedney Way, White Plains, NY 10605 (US). STEVENS, Sean; 355 Berry Street, #413, San Francisco, CA 94158 (US). DAVIS, Samuel; 332 West 88th Street, Apartment B2, New York, NY 10024 (US). BUCKLER, David, R.; 6 Erick Court, Chester, NJ 07930 (US). HO- SIAWA, Karolina, A.; 14 Church Street, 2nd Floor, — Tarrytown, NY 10591 (US). MURPHY, Andrew, J.; 10 Newton Court, Croton-on-Hudson, NY 10520 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, us SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: METHODS FOR MAKING FULLY HUMAN BISPECIFIC ANTIBODIES USING A COMMON LIGHT CHAIN & P1Ab • BsAb • P2 Ab < UJ S § C D> o '•£ 8< 500 400 300 200 100 3108 3109 3111 3112 l> •t 00 i-H en i-H o CJ FIG. 8 (57) Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.
priorityDate 2012-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419855749
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13907318

Total number of triples: 42.